摘要
目的 评价开普拓 (CPT 11)治疗中国晚期大肠癌患者的疗效及安全性。方法 CPT 113 0 0mg/m2 加生理盐水 2 0 0ml ,静脉点滴 3 0min ,每 3周 1次 ,3周为 1个周期 ,至少治疗 3个周期。结果 收治 14例 ,初治 7例 ,二线治疗 7例。在 13例可评价疗效的患者中 ,PR 3例 ,S 4例 ,P 6例 ,有效率为 2 3 .1% ,缓解期为 3～ 7个月。 3例PR患者均为初治者。治疗后中位生存期为9个月 ( 6～ 2 2个月 )。治疗后生存期大于 9个月者占 61.5 % ( 8/13 )。 14例患者均可评价不良反应 ,主要不良反应为延迟性腹泻、中性粒细胞减少及恶心、呕吐 ,其Ⅲ～Ⅳ度不良反应发生率分别为 42 .9%、71.4%、2 8.6%。结论 CPT 11治疗晚期大肠癌的疗效肯定 ,对中国人晚期大肠癌的治疗结果与国外报道一致 ,但治疗中应严密监测毒性反应。
Objective To evaluate the efficacy and safety of irinotecan(CPT 11) in chinese patients with advanced colorectal cancer.Methods All patients were treated with CPT 11 300 mg/m 2 intravenously every 3 weeks(at least 3 cycles).CPT 11 was mixed in 200 ml normal saline and infused intravenousely in 30 minutes.Results 14 patients were enrolled in this treatment.7 patients had no prior chemotherapy and seven patients were pretreated with 5 Fu based chemotherapy.Thirteen patients were evaluable for efficacy and fourteen for adverse reaction.Three patients achieved partial response,four stablization and six progression.The response rate was 23.0% and response duration was from three to seven months.The median survival time was 9 months(6～22months).61.5%(8/13)patients survived over 9 months.The major toxicity were delayed diarrhea,neutropenia and nause/vomiting.The incidence of grade Ⅲ/Ⅳ toxicity was 42.9%,71.4%,28.6% respectively.Conclusion CPT 11 has definite activity in the treatment of advanced colorectal cancer.The clinical results in chinese patients are comparable with the reported experience in western countries.The adverse reaction during treatment must be closely monitored.
出处
《实用癌症杂志》
2000年第4期423-425,共3页
The Practical Journal of Cancer
关键词
开普拓
晚期大肠癌
药物疗法
Irinotecan(CPT 11)
Advanced colorectal cancer
